0.05
+2.04%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Control Bionics
Its shares trade on ASX under the ticker CBL.AX. It has been listed since 7 December 2020. In the fiscal year to 30 June 2025, it reported revenue of A$7.0m and a net loss of A$6.1m. At that date it held total assets of A$8.2m and shareholders' equity of A$5.5m.
Control Bionics Ltd. engages in the manufacture, design, and sale of wireless wearable electromyography (EMG) based augmentative and alternative communication (AAC) technology. The company assists patients whose ability to communicate verbally or through text and social media is compromised by illnesses, such as motor neuron disease, amyotrophic lateral sclerosis, and others. Its NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as Electromyography output. This output is then sent wirelessly through the NeuroNode to a personal computer, enabling speech and other computer-controlled functions, such as email and texting. Its core systems include NeuroNode Trilogy, NeuroNode Duo, Eye-gaze Duo, and DROVE. Its technology is integrated with eye-gaze technology, whereby the eye gaze enables a cursor to be moved on a computer screen, driven like a mouse, and the NeuroNode acts like the mouse button.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 7 Dec 2020
Leadership
Pay as last reported
- Dr. Samuel StrafaceNon-Executive Independent Chairman of the Board
- Mr. Jeremy SteeleChief Executive Officer, Managing Director, Executive Director, since 2023
- Ms. Shannon BoothroydChief Financial Officer
- Mr. Todd TylerUS Country ManagerA$240,246
- Mr. Brett CrowleyCompany Secretary
- Dr. Stephanie PhillipsDirector
- Prof. Robert HeardNon-Executive Independent Director
- Mr. Damian LismoreNon-Executive Independent DirectorA$47,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Control Bionics Ltd. manufactures NeuroNode Trilogy for motor neuron disease patients in Australia.
- NeuroNode Duo and Eye-gaze Duo integrate eye-gaze technology for enhanced communication.
- DROVE is a core system enabling wireless communication for AAC users.
Weaknesses
- The company's focus on Health Care sector limits market diversification.
- NeuroNode technology requires specific medical conditions for effective use.
- Limited product range compared to broader Health Care competitors.
Opportunities
- Expanding NeuroNode technology to new countries like Germany could increase market reach.
- Growing demand for AAC technology in the Health Care industry presents opportunities.
- The NeuroNode Trilogy can be adapted for additional medical applications.
Threats
- Competition from established Health Care companies may reduce market share.
- Regulatory changes in the Health Care sector could impact product approval.
- Economic downturns might affect funding for medical technology purchases.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.